Softomotive: Empowering Citizen Developers in Japan, South Korea and China Master RPA
16.12.2019 09:00:00 EET | Business Wire | Press release
Softomotive, the fastest growing Robotic Process Automation (RPA) provider trusted by over 9000 clients globally, announces the localization of its comprehensive free online RPA training to meet the increasing demand of Softomotive’s RPA solutions across 3 new markets: Japan, South Korea and Greater China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005029/en/
Softomotive expands Free online RPA training to 3 new markets: Japan, South Korea and Greater China. (Photo: Business Wire)
Together with the English version, Softomotive’s courses in RPA are now available in Japanese, Mandarin and Korean, with more local versions to come. WinAutomation users in Asia can now benefit from a more tailored experience and master RPA skills through the fully localized curriculum including the on-demand video courses, fact-sheets and quizzes.
“With the localized version of Softomotive’s RPA courses we are able to help even more developers and professionals master RPA skills covering Attended and UnAttended Automation.” says Marios Stavropoulos, Co-Founder and CEO for Softomotive. “By providing WinAutomation courses in Korean, Japanese, and Mandarin we are enabling the growth and adoption of RPA, making it much easier for organizations in those regions to train their employees as they seek to deploy and implement RPA”.
Continuing on its mission to improve the employability quotient of professionals and developers, Softomotive began working with channel partners who have both domain and linguistic expertise to improve the quality of the translations.
Several of our customers in South Korea and Japan also commented on the value of having localized courses on WinAutomation. One said that having Korean courses available is extremely helpful in educating employees and helping citizen developers start creating automations for the business much faster.
The official reveal of the localized courses was done in front of clients and partners in a series of events and meetings Seoul (South Korea), Tokyo (Japan) and Bengaluru (India). During these events, Softomotive’s leadership highlighted the role of Asia-Pacific region as one where RPA adoption is expected to see tremendous growth. The successful events and meetings served as a great platform to showcase how Softomotive’s People1st Approach to RPA, a bottom-up approach giving the power of automation to employees, is enabling businesses locally in South Korea, Japan and Greater China respond to the pressures of reduced labor productivity, following the recent regulations on working hours and work styles.
With the latest updates to the Softomotive Academy, learners from Japan, South Korea and China can obtain a Certification and Diploma in Robotic Process Automation.
Join
Entering the world of the Softomotive Academy is the first step to gaining credibility.
The online RPA learning portal provides an intuitive web-based interface that is accessible from any device (including mobile). Professionals can enroll and discover a rich catalogue of video-based RPA tutorials that support on-demand and self-paced learning on Attended and Unattended Automation.
Learn
Automation knowledge is fast becoming an essential skill set in the labor market.
The RPA Academy offers easy-to-follow individual courses helping learners to master RPA skills covering Attended and Unattended automation. Training ranges from a solid foundation on Robotic Desktop Automation (RDA) and enterprise RPA, to the development of complex process automation via scripting, and the advanced management and monitoring of software robots.
Grow
Receiving an Accreditation in Softomotive’s Process Automation solutions, learners become part of a global network of thousands of professionals already helping their respective organizations accelerate their digitization efforts. A Diploma in RPA enables professionals and developers stay ahead of the rest in this exciting industry. Learners can watch RPA courses at any time tailored for specific roles or can fully customize their learning experience based on their personal learning objectives.
Visit the Softomotive Academy to see the RPA courses in Japanese, Korean and Mandarin.
About Softomotive
Softomotive is one of the leading worldwide providers of Robotic Process Automation (RPA) solutions, trusted by more than 9,000 companies worldwide. Both attended and unattended RPA are delivered through powerful, robust RPA technology, from desktop installation to server-based software which is quick to deploy, easy to use and provides the best value for money
WinAutomation is the world’s best Robotic desktop automation (RDA) tool and provides a powerful, robust and easy to use Windows-based platform for building software robots.
ProcessRobot is a leading enterprise RPA platform, including enterprise grade security and controls, with links to best-of-breed AI technologies.
#ProcessRobot #Softomotive #WinAutomation
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191215005029/en/
Contact information
For more information:
Jesus Kallergis
Softomotive Press Office
Email@ press@softomotive.com
Tel: +44 207 048 2000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom